The Effectiveness of Acupuncture for Complications in Critically Ill Patients

June 25, 2021 updated by: Yu-Chen Lee, China Medical University Hospital

The Effectiveness of Acupuncture for Complications in Critically Ill Patients: Multiple Centers a Double-Blind Randomized Control Trial

Introduction:

Intensive care unit (ICU) is a special department in the health care facility. Although with high development of modern medicine nowadays, the average mortality rate in ICU is still around 7 to 20 %. There are a few tricky problems that intensivists and ICU nurses faced very often, including ICU delirium, arrhythmia and poor digestion problem that will all affect the mortality and morbidity rate of critical care patients.

Methods: A randomized control trial will examine the effect of press tack acupuncture vs. press tack placebos. The patients will be randomly divided (1:1) into one of two groups. A total of 80 ICU patients will have to meet the following criteria: age 20-90, newly ICU admission(<48 hours), APACHE score <30, one or no inotropic medicine use, FiO2< 60%. Three interventions will be given in each group. The main outcomes will be the incidence of arrhythmia, delirium, and poor digestion and the severity of pain. We will also record ICU mortality, ICU stays and hospital days.

Study Overview

Detailed Description

Introduction:

Intensive care unit (ICU) is a special department in the health care facility. Although with high development of modern medicine nowadays, the average mortality rate in ICU is still around 7 to 20 %. There are a few tricky problems that intensivists and ICU nurses faced very often, including ICU delirium, arrhythmia and poor digestion problem that will all affect the mortality and morbidity rate of critical care patients.

Methods: A randomized control trial will examine the effect of press tack acupuncture vs. press tack placebos. The patients will be randomly divided (1:1) into one of two groups. A total of 80 ICU patients will have to meet the following criteria: age 20-90, newly ICU admission(<48 hours), APACHE score <30, one or no inotropic medicine use, FiO2< 60%. Three interventions will be given in each group. The main outcomes will be the incidence of arrhythmia, delirium, and poor digestion and the severity of pain. We will also record ICU mortality, ICU stays and hospital days.

Expected outcome: The study finding will help to determine the therapeutic effect of acupuncture for ICU complications.

Other information: This study will be conducted in the ICU departments of China medical hospital and Asia University Hospital, Taichung city, Taiwan. The study is conducted on stable ICU patients and we don't anticipate any serious risk for adverse events following the intervention.

Study Type

Interventional

Enrollment (Anticipated)

80

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 90 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Age 20--90

    • newly ICU admission (<48 hours)
    • APACHE score <30
    • Less than 3 inotropic medicine use
    • Fi02< 60%.

Exclusion Criteria:

  • • Coagulopathy: Prolong Prothrombin Time (PPT) activated Partial Thromboplastin Time (aPTT) more than 4 times

    • Thrombocytopenia - low platelet count
    • Clinically unstable: receiving two or more inotropic agents or Fraction of Inspired Oxygen (Fi02) >60%
    • Primary central nervous system disorder: stroke, traumatic brain injury, central nervous system infections, brain tumors, recent intracranial surgery
    • Already under other traditional medicine intervention during hospitalization
    • Skin damage of more than 20% of the body skin.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Acupuncture with press tack needle group (Acu)
Patients in acupuncture group will receive traditional Chinese acupuncture using Press Tack Needle (PYONEX 0.20 x l.5mm made by Seirin Corporation). The following acupoints will be used: HT 7 (Shen Men), PC 6 (Nei Guan), LU 9 (Tai yuan), LI 4 (He Gu), SP 3 (Tai Bai,) ST 44 (Nei ting), LIV 3 (Tai Chong). The treatment will use bilateral acupuncture Interventions will be given on day 1, 3, and 5 after patient's enrolment.
Patients enrolled will receive intervention in a form of either press tack acupuncture needles or press tack placebos. Three total intervention sessions will be taken place on day 1,3,5 from patient's enrolment. Needles/placebos skin withdrawal will be done 48 hours after treatment by an acupuncture doctor or by a trained ICU nurne. In cases when a patient will be transferred from the ICU, the 3 study interventions will be continued in the new ward.
Other Names:
  • Press Tack Needle/ sticker needle/ PYONEX
Placebo Comparator: Placebo group press tack placebo (Con)
Patients randomized to the control group will receive a press lack placebo (made by Seirin Corporation), which looks identical to press tack needles but, with no needle element. The point selection will be identical to the acupuncture group: HT 7 (Shen Men), PC 6 (Nei Guan), LU 9 (Tai yuan), L1 4 (He Gu), SP 3; (Tat Bai), ST 44 (Ne1 tmg), LIV 3 (Tat Chong). Interventions will be given on days 1, 3, and 5 after the patient's enrolment.
pess tack stickers without a needle
Other Names:
  • PYONEX placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
arrhythmia
Time Frame: at the patient's ICU discharge, on average 1 week
incidence of arrhythmia
at the patient's ICU discharge, on average 1 week
delirium
Time Frame: at the patient's ICU discharge, on average 1 week
4 or more points according to the Intensive Care Delirium Screening Checklist (ICDSC)(0-8 scale, score of less than 4 points indicate no delirium, 4 or more indicate delirium) and a Richmond Agitation-Sedation Scale (RASS) score of: +l, +2, +3, +4 - 1, -2 (score meanings +1 - 4 = levels of agitation, -1-4= levels of sudation, 0 = normal mental state.
at the patient's ICU discharge, on average 1 week
feeding intolorance
Time Frame: at the patient's ICU discharge, on average 1 week
measured by days to reach the target Energy Fxpenditure
at the patient's ICU discharge, on average 1 week
pain in the intensive care unit (ICU)
Time Frame: at the patient's ICU discharge, on average 1 week
For pain the Numeric Rating scale will be applied in patients that are able to express their self. As well as the Behavioral pain scale. The Critical Care Pain Observation Tool (CPOT) 0-8, will also be filled by the doctor and nurses along with the dose of fentanyl, hydromorphone methadone, morphine, and remifentanil and other analgesic medications.
at the patient's ICU discharge, on average 1 week
dose of arrhythmia drugs
Time Frame: at the patient's ICU discharge, on average 1 week

the dose of Adenosine, calcium channel blockers, or beta-blocking agents or other arrhythmia drugs

.

at the patient's ICU discharge, on average 1 week
dose of use of prokinetic drugs
Time Frame: at the patient's ICU discharge, on average 1 week
does of metoclopramide, Erythromycin or other prokinetic drugs
at the patient's ICU discharge, on average 1 week
analgesic medication use
Time Frame: at the patient's ICU discharge, on average 1 week
dose of fentanyl, hydromorphone methadone, morphine, and remifentanil and other analgesic medications.
at the patient's ICU discharge, on average 1 week
delirium drug use
Time Frame: at the patient's ICU discharge, on average 1 week
addition to drug use (a daily dose of sedative drugs, muscle relaxant, or atypical antipsychotics IV Haloperidol Benzodiazepines, Precedex, Propofol and oral Quediapine)
at the patient's ICU discharge, on average 1 week

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
the use of Parental nutrition
Time Frame: at the patient's ICU discharge, on average 1 week
patients who cannot digest with daily NG tube: drainage: more than 500ml per day or severe diarrhea more the 1000 ml per day
at the patient's ICU discharge, on average 1 week
the need for a post-pyloric tube
Time Frame: at the patient's ICU discharge, on average 1 week
patients who cannot digest with daily NG tube and by doctor decision
at the patient's ICU discharge, on average 1 week
vomitus
Time Frame: at the patient's ICU discharge, on average 1 week
in microliters
at the patient's ICU discharge, on average 1 week
diarrhea
Time Frame: at the patient's ICU discharge, on average 1 week
in microliters
at the patient's ICU discharge, on average 1 week
constipation days
Time Frame: at the patient's ICU discharge, on average 1 week
3 days without stool discharge
at the patient's ICU discharge, on average 1 week
gastrointestinal (GI) bleeding
Time Frame: at the patient's ICU discharge, on average 1 week
in number of times
at the patient's ICU discharge, on average 1 week
albumin blood levels
Time Frame: at the patient's ICU discharge, on average 1 week
serum albumin blood levels
at the patient's ICU discharge, on average 1 week
Intravenous (IV) injected albumin
Time Frame: at the patient's ICU discharge, on average 1 week
IV injected albumin in grams
at the patient's ICU discharge, on average 1 week
heart rate
Time Frame: day 1,3,5,7
number of beats per minute
day 1,3,5,7
blood pressure
Time Frame: day 1,3,5,7
systolic and diastolic blood pressure in mm Hg
day 1,3,5,7
SpO2 oxygen saturation
Time Frame: day 1,3,5,7
Sp02 oxygen saturation levels
day 1,3,5,7
Respiratory rate
Time Frame: day 1,3,5,7
measured by number of breath in one minute
day 1,3,5,7
mean arterial pressure
Time Frame: day 1,3,5,7
average pressure in a patient's arteries during one cardiac cycle
day 1,3,5,7
Body temperature
Time Frame: at the patient's ICU discharge, on average 1 week
number of days of body temperature over 38 °C
at the patient's ICU discharge, on average 1 week
ventilator data
Time Frame: day 1,3,5,7
ventilator data
day 1,3,5,7
Overall Satisfaction of patient family
Time Frame: at the patient Hospital discharge, on average 1 month
Overall Satisfaction of patient family will be measured by the European Family Satisfaction with Care in the Intensive Care Unit (EURO FS-ICU).
at the patient Hospital discharge, on average 1 month
mechanical ventilation days days
Time Frame: at the patient Hospital discharge, on average 1 month
number of days under mechanical ventilation
at the patient Hospital discharge, on average 1 month
ICU stay
Time Frame: at the patient's ICU discharge, on average 1 week
number of admission days to the ICU
at the patient's ICU discharge, on average 1 week
hospital days
Time Frame: at the patient Hospital discharge, on average 1 month
number of admission days to the hospital
at the patient Hospital discharge, on average 1 month
ICU mortality
Time Frame: at the patient's ICU discharge, on average 1 week
number of patients died in the ICU
at the patient's ICU discharge, on average 1 week
Hospital mortality
Time Frame: at the patient Hospital discharge, on average 1 month
number of patients died in the hospital
at the patient Hospital discharge, on average 1 month
cost of hospital admission
Time Frame: at the patient Hospital discharge, on average 1 month
cost of hospital admission in New Taiwan Dollars {TWD)
at the patient Hospital discharge, on average 1 month
cost of ICU admission
Time Frame: at the patient's ICU discharge, on average 1 week
cost of ICU admission in New Taiwan Dollars {TWD).
at the patient's ICU discharge, on average 1 week
acupuncturist blinding
Time Frame: after intervention on day 5
blinding questioner will ask the acupuncturist to which group he/she guessed he/she applied the intervention
after intervention on day 5

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Yu-Chen Lee, China Medical University Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

August 1, 2021

Primary Completion (Anticipated)

July 30, 2022

Study Completion (Anticipated)

September 30, 2022

Study Registration Dates

First Submitted

June 22, 2021

First Submitted That Met QC Criteria

June 25, 2021

First Posted (Actual)

July 6, 2021

Study Record Updates

Last Update Posted (Actual)

July 6, 2021

Last Update Submitted That Met QC Criteria

June 25, 2021

Last Verified

June 1, 2021

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Delirium

Clinical Trials on pess tack acupuncture

Subscribe